Insider · CIK 0001427569

Viret Jean-Frederic

Reports to the SEC for 4 companies · ALISO VIEJO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001427569

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-05	SGPSpyGlass Pharma, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+17.5K sh	—	—	17,500
2024-04-05	NGM BIOPHARMACEUTICALS INCU Disposition from Tender	Chief Financial Officer	UDisposition from Tender	−3,038 sh	—	—	0
2024-04-05	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−450K sh	—	—	0
2023-12-01	NGM BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+450K sh	—	—	450,000
2021-02-01	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,402 sh	$10.05	+$74.4K	68,697
2021-02-01	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−7,402 sh	$21.55	−$160K	61,295
2021-02-01	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−7,402 sh	—	—	54,167
2021-01-25	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+40K sh	$10.05	+$402K	107,439
2021-01-25	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−40K sh	$20.10	−$804K	67,439
2021-01-25	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−6,144 sh	$19.00	−$117K	61,295
2021-01-25	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−40K sh	—	—	61,569
2021-01-11	CHRSCoherus Oncology, Inc.A Award	Chief Financial Officer	AAward	+31.3K sh	—	—	67,439
2021-01-11	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+62.5K sh	—	—	62,500
2021-01-10	CHRSCoherus Oncology, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−4,080 sh	$18.18	−$74.2K	36,189
2020-11-17	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−1,995 sh	$17.49	−$34.9K	38,769
2020-11-17	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+1,500 sh	$13.50	+$20.3K	40,269
2020-11-17	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−1,500 sh	—	—	110,241
2020-10-14	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−6,144 sh	$19.00	−$117K	40,423
2020-05-20	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−1,278 sh	$17.66	−$22.6K	46,567
2020-02-19	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,159 sh	$10.05	+$31.7K	50,000
2020-02-19	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−3,159 sh	$22.33	−$70.6K	46,841
2020-02-19	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,159 sh	—	—	101,569
2020-01-15	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+6,318 sh	$10.05	+$63.5K	53,159
2020-01-15	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−3,520 sh	$19.67	−$69.2K	49,639
2020-01-15	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−2,798 sh	$20.08	−$56.2K	46,841
2020-01-15	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,318 sh	—	—	104,728
2020-01-10	CHRSCoherus Oncology, Inc.A Award	Chief Financial Officer	AAward	+19.4K sh	—	—	22,668
2020-01-10	CHRSCoherus Oncology, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−7,077 sh	$17.73	−$125K	15,591
2020-01-10	CHRSCoherus Oncology, Inc.A Award	Chief Financial Officer	AAward	+31.3K sh	—	—	46,841
2020-01-10	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+62.5K sh	—	—	62,500
2019-11-20	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,159 sh	$10.05	+$31.7K	6,462
2019-11-20	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−3,159 sh	$19.59	−$61.9K	3,303
2019-11-20	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,159 sh	—	—	111,046
2019-11-18	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−3,112 sh	$18.88	−$58.8K	3,303
2019-10-18	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−1,388 sh	$19.02	−$26.4K	6,385
2019-10-16	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,159 sh	$10.05	+$31.7K	10,932
2019-10-16	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−3,159 sh	$19.00	−$60K	7,773
2019-10-16	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,159 sh	—	—	114,205
2019-09-23	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−740 sh	$21.78	−$16.1K	7,773
2019-09-18	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,159 sh	$10.05	+$31.7K	11,672
2019-09-18	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−3,159 sh	$20.44	−$64.6K	8,513
2019-09-18	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,159 sh	—	—	117,364
2019-08-21	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+6,318 sh	$10.05	+$63.5K	14,831
2019-08-21	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−260 sh	$20.73	−$5,388.682	14,571
2019-08-21	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−6,058 sh	$21.75	−$132K	8,513
2019-08-21	CHRSCoherus Oncology, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,318 sh	—	—	120,523
2019-08-19	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$19.04	−$57.1K	8,513
2019-06-19	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−667 sh	$20.00	−$13.3K	11,513
2019-06-19	CHRSCoherus Oncology, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,159 sh	$10.05	+$31.7K	14,672
2019-06-19	CHRSCoherus Oncology, Inc.S Sale	Chief Financial Officer	SSale	−3,059 sh	$20.32	−$62.2K	11,613

Recent filings

Accepted (ET)
Feb 94
Viret Jean-Frederic0001427569-26-000008
SEC(opens sec.gov)
Apr 84
Viret Jean-Frederic0000950170-24-042611
SEC(opens sec.gov)
Dec 44
Viret Jean-Frederic0001209191-23-057214
SEC(opens sec.gov)
Feb 34
Viret Jean-Frederic0001567619-21-002141
SEC(opens sec.gov)
Jan 274
Viret Jean-Frederic0001567619-21-001600
SEC(opens sec.gov)
Jan 134
Viret Jean-Frederic0001567619-21-000982
SEC(opens sec.gov)
Jan 124
Viret Jean-Frederic0001567619-21-000922
SEC(opens sec.gov)
Nov 194
Viret Jean-Frederic0001567619-20-020095
SEC(opens sec.gov)
Oct 164
Viret Jean-Frederic0001567619-20-017922
SEC(opens sec.gov)
May 224
Viret Jean-Frederic0001567619-20-011016
SEC(opens sec.gov)
Feb 214
Viret Jean-Frederic0001567619-20-004636
SEC(opens sec.gov)

Companies

Address

C/O SPYGLASS PHARMA, INC. 27061 ALISO CREEK RD., SUITE 100

ALISO VIEJO, CA, 92656